Opiate sparing effect of fixed combination of diclophenac and orphenadrine after
unilateral total hip arthroplasty: A double-blind, randomized,
placebo-controlled, multi-centre clinical trial.
Author(s): Gombotz H, Lochner R, Sigl R, Blasl J, Herzer G, Trimmel H.
Affiliation(s): Department of Anaesthesiology and Intensive Care Medicine, General Hospital Linz,
Austria. hans.gombotz@akh.linz.at
Publication date & source: 2010, Wien Med Wochenschr. , 160(19-20):526-34
Multimodal pain management combines analgesics to improve analgesia and reduce
side effects. This study investigates the fixed combination of diclophenac and
orphenadrin (Neodolpasse(®) Infusion Solution) in patients after unilateral total
hip arthroplasty (THA). This prospective, randomized, double-blind,
placebo-controlled, multi-centre clinical study enrolled 120 patients receiving
patient-controlled analgesia (PCA). Isotonic saline was infused as placebo. The
primary efficacy goal was defined as reduction of PCA analgesics used over the
first 24 h post-surgery. The study used a three-stage group sequential test
design with two interim analyses. Analgesia was monitored by visual analogue
scale and verbal rating. Infusion of the Neodolpasse(®) Infusion Solution
resulted in a significant reduction in the PCA analgesic requirements by
approximately 30% (38.7 ± 21.3 mg vs. 55.9 ± 31.1 mg; p = 0.0004) while
maintaining adequate analgesia and patient safety. This study demonstrates that
Neodolpasse(®) Infusion Solution significantly reduces PCA analgesic requirements
without compromising analgesic effectiveness and safety in THA patients.
|